Crossmark

Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

Crossref DOI link: https://doi.org/10.1186/S12913-021-07025-8

Published: 2021-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Turongkaravee, Saowalak http://orcid.org/0000-0003-1897-3495
Jittikoon, Jiraphun

Rochanathimoke, Onwipa

Boyd, Kathleen

Wu, Olivia

Chaikledkaew, Usa http://orcid.org/0000-0001-9457-9823
Funding

Funding for this research was provided by:

International Research Network-the Thailand Research Fund (IRN60W003)

Health Systems Research Institute (HSRI61-080)
License Information

Text and Data Mining valid from 2021-10-02

Version of Record valid from 2021-10-02
More Information

Article History

Received: 17 December 2020

Accepted: 14 September 2021

First Online: 2 October 2021

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below